GLP-1 Medications
What they are, how they work, and how Teledoc prescribes them
GLP-1 medications: the most significant advance in metabolic medicine in a generation.
GLP-1 receptor agonists are not diet pills. They are metabolic hormones that work with your body’s own biology to improve insulin secretion, reduce hunger, slow digestion, and drive measurable, sustained weight loss. Teledoc prescribes them as part of a phenotype-matched, doctor-supervised programme — never in isolation.
⚠️ GLP-1 medications are prescription drugs. At Teledoc, every prescription is issued by a registered doctor after a clinical assessment and metabolic phenotyping. We do not prescribe GLP-1 medications without a doctor consultation and a treatment plan.
What is GLP-1 and why does it matter for weight loss and diabetes?
GLP-1 stands for Glucagon-Like Peptide-1. It is a hormone naturally produced in the gut after eating. Its job is to tell the body that food has arrived — triggering insulin release, suppressing glucagon, slowing gastric emptying, and signalling the brain that you are full.
In people with obesity, insulin resistance, Type 2 diabetes, or neurogenic appetite dysregulation, this natural GLP-1 signal is weakened or delayed. GLP-1 receptor agonists are synthetic versions of this hormone that bind to the same receptors and restore the signal — consistently, reliably, and with a duration that far exceeds the natural hormone.
What GLP-1 receptor agonists do in the body
| Mechanism | What it means for the patient |
|---|---|
| Stimulate glucose-dependent insulin secretion | More insulin released when glucose is high — but not when it is low, avoiding hypoglycaemia |
| Suppress glucagon release | Liver stops releasing stored glucose unnecessarily — reduces fasting and post-meal glucose levels |
| Slow gastric emptying | Food moves more slowly from stomach to intestine — reduces post-meal glucose spikes, increases satiety duration |
| Act on hypothalamic appetite centres | Directly reduces hunger signals from the brain — the most important mechanism for weight loss |
| Reduce visceral fat preferentially | Weight loss is disproportionately from metabolically dangerous abdominal fat, not muscle |
| Improve insulin sensitivity | Tissues become more responsive to insulin over time — the core of diabetes reversal |
| Cardioprotective effects (semaglutide) | Demonstrated reduction in major cardiovascular events in landmark CVOT trials |
Semaglutide and tirzepatide: what’s the difference?
Teledoc uses two GLP-1 receptor agonists in the Teledoc Weight Loss programme, prescribed based on your metabolic phenotype, baseline labs, and clinical indication. Both are weekly subcutaneous injections. The choice between them is a clinical decision — not a patient preference.
| Semaglutide (Ozempic® / Wegovy®) | Tirzepatide (Mounjaro®) | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Mechanism | Activates GLP-1 receptor only | Activates both GLP-1 and GIP receptors simultaneously — dual agonism |
| Weight loss | 10–15% body weight reduction at 68 weeks (SUSTAIN / STEP trials) | 15–22% body weight reduction at 72 weeks (SURMOUNT trials) — superior outcomes |
| HbA1c reduction | 1.5–2.0% reduction | 2.0–2.5% reduction — superior glycaemic control |
| Dosing | 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg weekly (titrated over 16–20 weeks) | 2.5 mg → 5 mg → 7.5 mg → 10 mg → 15 mg weekly (titrated over 20 weeks) |
| Best phenotype match | Neurogenic appetite, insulin resistance, cardiovascular risk, general T2DM | Insulin-resistant, pre-diabetic, dyslipidaemic, NAFLD — phenotypes where dual agonism adds significant benefit |
| Availability in India | Available — Ozempic (T2DM indication) more readily stocked | Available but stock varies by city — may need pharmacy coordination |
| Cost in India (approx.) | ₹8,000–14,000 per month (dose-dependent) | ₹12,000–18,000 per month (dose-dependent) — separate from programme fee |
| Teledoc position | First-line for most phenotypes; well-studied, widely available | Pharmacologically superior for insulin-resistant / pre-diabetic / dyslipidaemic phenotypes — prescribed where indicated |
Teledoc clinical position on tirzepatide vs. semaglutide:
Tirzepatide is pharmacologically superior for the insulin-resistant, pre-diabetic, and dyslipidaemic phenotypes due to its dual GLP-1 + GIP agonism. However, prescribing in India must account for real-world availability and cost. Our doctors make the prescribing decision after phenotype identification and a frank discussion of both options with the patient.
Is GLP-1 therapy right for you?
GLP-1 medication is not appropriate for every patient — and at Teledoc, it is never the starting point. We identify your metabolic phenotype first, attempt lifestyle intervention, and prescribe GLP-1 only where the clinical case is clear. Here is who benefits most.
| Patient profile | Why GLP-1 helps | Expected benefit |
|---|---|---|
Insulin-resistant / pre-diabetic Fasting insulin elevated, HOMA-IR >2.5 |
Dual mechanism: improves insulin sensitivity + reduces hepatic glucose output | HbA1c normalisation, 10–15% weight loss, HOMA-IR improvement |
Type 2 diabetes, overweight HbA1c 7–10%, BMI >25 |
Restores incretin effect lost in T2DM; reduces medication burden over time | HbA1c reduction 1.5–2.5%, weight loss, possible medication tapering |
Neurogenic appetite phenotype Compulsive eating, cannot sustain restriction |
Directly suppresses hypothalamic hunger signals — the root mechanism | Appetite regulation, reduced cravings, sustained caloric reduction without willpower |
Metabolic obesity High visceral fat, fatty liver (NAFLD) |
Preferential visceral fat reduction; hepatic steatosis improvement demonstrated in trials | Waist circumference reduction, liver enzyme normalisation, lipid improvement |
PCOS with insulin resistance Hyperandrogenism + metabolic dysfunction |
Insulin sensitisation breaks the hyperinsulinaemia–androgen cycle | Improved cycles, reduced androgen symptoms, weight loss, insulin normalisation |
Dyslipidaemia + metabolic syndrome High TG, low HDL, elevated CRP |
GLP-1 + GIP dual agonism (tirzepatide) produces superior lipid correction | TG reduction, HDL improvement, CRP reduction, cardiovascular risk lowering |
Who should NOT use GLP-1 medications
| Contraindication | Reason |
|---|---|
| Personal or family history of medullary thyroid carcinoma | GLP-1 receptors present in thyroid tissue — absolute contraindication in guidelines |
| Multiple Endocrine Neoplasia Type 2 (MEN2) | Associated medullary thyroid cancer risk — absolute contraindication |
| Personal history of pancreatitis | GLP-1 agents associated with rare pancreatitis risk — avoid in prior pancreatitis history |
| Type 1 diabetes (insulin-dependent) | Not indicated as primary therapy — should not replace insulin in T1DM |
| Pregnancy or breastfeeding | Safety data insufficient — avoid; adequate contraception required during use |
| Severe gastroparesis | Gastric emptying slowing mechanism contraindicated in existing gastroparesis |
| Severe renal impairment (eGFR <30) | Caution required — clinical assessment needed before prescribing |
We never prescribe GLP-1 medication on Day 1.
GLP-1 therapy is a powerful metabolic tool — but it delivers its best results when prescribed to the right phenotype, at the right dose, within a structured lifestyle programme. At Teledoc, GLP-1 prescription follows a defined clinical pathway.
| Step | What happens | Timing |
|---|---|---|
| STEP 1 Metabolic assessment |
Initial doctor consultation. Blood panel ordered: fasting insulin, HOMA-IR, HbA1c, lipid panel, thyroid profile, cortisol, sex hormones (where indicated). Metabolic phenotype determined. | Week 1–2 |
| STEP 2 Lifestyle programme begins |
Personalised Indian vegetarian diet chart, exercise plan, nutraceutical stack, and WhatsApp coaching begin. GLP-1 is NOT yet prescribed — lifestyle change is always the first intervention. | Week 3–4 |
| STEP 3 Week 10 decision gate |
Formal clinical review. Repeat labs. Assessment of:
|
Week 10 |
| STEP 4 Initiation and titration |
GLP-1 started at lowest dose. Titration schedule followed (every 4 weeks). Side effects monitored. Dose adjusted for tolerance and response. Medication supplied via PharmEasy, 1mg, or Netmeds. | Week 10–30 |
| STEP 5 Monthly monitoring |
Monthly doctor review. Weight, HbA1c, blood pressure, and patient-reported outcomes tracked. Dose adjustments made as needed. Plan evolves with patient's metabolic response. | Monthly ongoing |
Dosing protocols for semaglutide and tirzepatide
All GLP-1 medications are titrated slowly — starting at the lowest effective dose and increasing every 4 weeks. Slow titration is not optional: it is the primary strategy for minimising gastrointestinal side effects and improving long-term tolerance.
Semaglutide titration schedule
| Month | Weekly dose | Clinical purpose |
|---|---|---|
| Month 1 | 0.25 mg / week | Tolerability phase — assess GI response, not therapeutic dose |
| Month 2 | 0.5 mg / week | Initial therapeutic dose — appetite suppression begins |
| Month 3 | 1.0 mg / week | Standard maintenance dose — significant glucose and weight effect |
| Month 4+ | 2.0 mg / week | Maximum dose for T2DM / obesity indications — if clinically indicated |
Dose escalation may be paused or slowed if GI side effects are significant. Doctor-supervised titration only.
Tirzepatide titration schedule
| Month | Weekly dose | Clinical purpose |
|---|---|---|
| Month 1 | 2.5 mg / week | Tolerability phase — GI adaptation, not therapeutic |
| Month 2 | 5 mg / week | Initial therapeutic dose — insulin sensitisation begins |
| Month 3 | 7.5 mg / week | Mid-range dose — dual agonism producing measurable metabolic effect |
| Month 4 | 10 mg / week | Standard high-dose maintenance — optimal for insulin-resistant phenotype |
| Month 5+ | 12.5–15 mg / week | Maximum dose — for patients requiring full metabolic correction |
Tirzepatide dose escalation is slower than semaglutide due to the dual receptor mechanism. Monthly review mandatory.
Side effects: what to expect and how we manage them
GLP-1 medications have a well-understood side effect profile. The vast majority are gastrointestinal and occur during the dose titration phase — they typically resolve as the body adjusts. Serious adverse events are rare.
| Side effect | Frequency | When it occurs | How Teledoc manages it |
|---|---|---|---|
| Nausea | Very common (30–40%) | First 4–8 weeks of each dose step | Slow titration, eat small meals, avoid fatty food, ginger-based remedies; reduce dose if severe |
| Reduced appetite / early satiety | Very common — intended effect | From Week 2 onwards | Monitor for adequate protein and micronutrient intake; dietician support in higher plans |
| Vomiting | Common (10–20%) | Peak during dose escalation | Hydration protocol; dose held if persistent; slow re-titration after resolution |
| Diarrhoea | Common (10–15%) | Variable, often early | Usually self-limiting; dietary fibre adjustment; probiotic support if needed |
| Constipation | Common (10–15%) | After nausea/diarrhoea phase | Hydration increase, dietary fibre up, magnesium supplementation |
| Injection site reactions | Uncommon (<5%) | Any time | Rotate injection sites; use room-temperature pen; correct technique education |
| Headache | Uncommon (<10%) | Early weeks | Usually resolves; ensure hydration; dose timing adjustment if needed |
| Pancreatitis (rare) | Rare (<0.3%) | Can occur at any time | Stop immediately if upper abdominal pain radiates to back; attend emergency care; do not restart |
| Hypoglycaemia | Rare (GLP-1 alone) | Usually only if combined with sulphonylurea / insulin | Monitor glucose if on other diabetes medication; dose adjustment of co-medications |
💡 The most important strategy for tolerating GLP-1 medications is slow dose titration. At Teledoc we never rush escalation. Patients are monitored via WhatsApp between consultations and can pause or reduce dose at any time with doctor guidance. This is why a supervised programme produces far better tolerability and adherence than self-administered, unsupervised use.
Self-injection: it is simpler than it sounds
Both semaglutide and tirzepatide come in pre-filled auto-injector pens. The injection is subcutaneous — under the skin, not into muscle — using an ultra-fine needle. Most patients describe it as nearly painless. Your doctor and care team walk you through technique on Day 1 and are available on WhatsApp for any questions.
| Step | What to do |
|---|---|
| 1 | Choose your injection site: abdomen (at least 5 cm from navel), front of thigh, or upper arm. Rotate sites each week. |
| 2 | Remove the pen from the refrigerator 30 minutes before use. Injecting cold medication increases discomfort and nausea. |
| 3 | Check the pen window — the liquid should be clear and colourless. Do not use if cloudy or discoloured. |
| 4 | Clean the injection site with an alcohol swab. Allow it to dry completely. |
| 5 | Remove the pen cap. Do not shake the pen. Press firmly against the skin and press the button until you hear a click. |
| 6 | Hold the pen in place for 6 seconds after the click. This ensures the full dose is delivered. |
| 7 | Dispose of the used pen in a sharps container. Never recap used needles. Keep unused pens in the refrigerator (2–8°C). |
Storage and handling
Unused pens: store in refrigerator at 2–8°C (not freezer). Do not expose to direct sunlight.
In-use pen: can be stored at room temperature (below 30°C) for up to 56 days (semaglutide) or 21 days (tirzepatide).
If pen is dropped or damaged: do not use. Contact your care team.
Travel: use an insulated medication pouch; declare at airport security as injectable medication.
GLP-1 medication without lifestyle change is a wasted opportunity.
Clinical trials show that GLP-1 medications combined with structured lifestyle intervention produce 50–70% greater weight loss and metabolic improvement than medication alone. The drug creates the conditions for change — the lifestyle programme makes that change permanent.
| Lifestyle pillar | How GLP-1 enhances it |
|---|---|
| Diet — reduced caloric intake | GLP-1 suppresses appetite, making dietary adherence dramatically easier. Patients no longer fight hunger — the biological signal changes. |
| Exercise — improved energy and capacity | Weight loss from GLP-1 reduces joint load and fatigue, making exercise more accessible. Insulin sensitisation improves exercise-induced glucose disposal. |
| Sleep — less disruptive to circadian glucose | Weight loss and reduced nocturnal glucose fluctuations improve sleep quality, which in turn improves insulin sensitivity. |
| Stress management — cortisol attenuation | GLP-1 has direct effects on the hypothalamic-pituitary axis that may reduce cortisol-driven glucose elevation — especially relevant for cortisol phenotype patients. |
| Resistance training — muscle preservation during weight loss | GLP-1-assisted weight loss can include muscle loss if protein intake is inadequate. Resistance training and high-protein diet preserve lean mass during fat loss. |
🏆 Teledoc's integrated approach: GLP-1 medication + Indian vegetarian phenotype-matched diet + exercise plan + WhatsApp coaching + monthly doctor review.
This is not a drug dispensing service. This is a metabolic programme that includes drug therapy where it is clinically justified.
Choose the level of support that fits you
GLP-1 prescription is available across all plans. The difference between plans is the level of dietary, lifestyle, coaching, and monitoring support alongside the prescription. Medication costs are separate from programme fees.
GLP-1 medication costs (semaglutide ₹8,000–14,000/mo | tirzepatide ₹12,000–18,000/mo) are separate from programme fees. Lab tests are charged separately .
Frequently asked questions about GLP-1 medications
Do I need GLP-1 medication to join the Teledoc programme?
No. GLP-1 medication is one tool in the programme — not a requirement. Many patients achieve excellent metabolic outcomes through diet, exercise, and nutraceuticals alone. GLP-1 is prescribed at the Week 10 clinical review, only when the phenotype and lab results indicate it will add meaningful benefit.
Can I get GLP-1 medication without a consultation?
No — and this is deliberate. GLP-1 medications require a prescription from a registered doctor. At Teledoc, every prescription is preceded by a consultation, a blood panel, and a clinical assessment. We do not operate as a drug dispensing service.
How long will I need to stay on GLP-1 medication?
Duration depends on your phenotype, degree of metabolic dysfunction, and response to treatment. Many patients with pre-diabetes or early T2DM can discontinue GLP-1 therapy after 12–24 months if weight and metabolic targets are sustained. Patients with severe insulin resistance or neurogenic appetite may benefit from longer-term use. This is a clinical decision made with your doctor, not a fixed timeframe.
What happens if I stop GLP-1 medication?
Studies show that stopping GLP-1 medication without concurrent lifestyle change leads to weight regain in most patients within 1 year. This is why the Teledoc programme emphasises lifestyle modification alongside medication. If medication is stopped, the dietary and exercise habits built during the programme provide the long-term protection.
Is tirzepatide better than semaglutide?
Tirzepatide produces superior weight loss and glycaemic outcomes in clinical trials — particularly in insulin-resistant and pre-diabetic phenotypes — due to its dual GLP-1 + GIP mechanism. However, cost, availability in India, and individual patient response are all factors in the prescribing decision. Your doctor will make a recommendation based on your specific phenotype and clinical picture.
Will insurance cover GLP-1 medication?
Most Indian health insurance policies currently do not cover GLP-1 medications prescribed for obesity or weight loss. Coverage may exist for T2DM indications under some corporate health plans. We recommend checking your policy. Our doctors can provide a prescription and supporting clinical documentation for reimbursement claims where applicable.
Can I use GLP-1 medication if I have PCOS?
Yes — GLP-1 therapy is particularly effective in PCOS patients with insulin resistance, which is the majority of PCOS cases in India. By improving insulin sensitivity, GLP-1 breaks the hyperinsulinaemia–androgen cycle that underlies many PCOS symptoms. It is used alongside the hormonal metabolic protocol in the Teledoc Weight Loss programme.
I am vegetarian. Are there any dietary interactions with GLP-1 medication?
The primary dietary consideration with GLP-1 therapy is protein adequacy. As appetite is suppressed, total caloric intake drops — but protein intake must be maintained at 1.2–1.6 g per kg of body weight to preserve muscle mass. Our diet charts are specifically designed to maintain protein targets on a reduced-calorie Indian vegetarian diet. Soya, low-fat paneer, hung curd, and legumes are the primary sources.
What are the pharmacy options for GLP-1 medication delivery?
Teledoc works with PharmEasy, 1mg, and Netmeds for medication delivery. Your doctor will issue a digital prescription that can be submitted directly to these platforms. Home delivery is available in most metro and Tier 1 cities. Stock availability, particularly for tirzepatide, may vary by city and month — our care team monitors this and can suggest alternatives.
GLP-1 therapy, prescribed right, changes metabolic trajectories.
Not as a shortcut. Not without a plan. As part of a doctor-supervised, phenotype-matched programme that addresses the root cause of weight gain and diabetes — not just the symptoms.